Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
DRUG:
MEN1611
i
Other names:
MEN1611, CH5132799, PA799, MEN-1611, MEN 1611, CH 5132799, PA-799
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Associations
(16)
News
Trials
Company:
Menarini, Roche
Drug class:
PI3K inhibitor
Related drugs:
‹
RTB101 (43)
PF-05212384 (31)
RG7440 (27)
chidamide (23)
GDC-0941 (22)
AN2025 (20)
GSK2126458 (17)
CUDC-907 (8)
rigosertib (7)
LY294002 (7)
PF-04691502 (6)
RP6530 (6)
LY3023414 (5)
GDC-0980 (4)
A66 (3)
enzastaurin (3)
GDC-0084 (3)
PI-103 (2)
AEZS 136 (1)
AEZS-129 (1)
AZD8835 (1)
BAY 1082439 (1)
CB-006-3 (1)
DFN-529 (1)
KU-0060648 (1)
OP-11 (1)
SB02024 (1)
SRX3262 (1)
SAR245408 (1)
CBL0102 (1)
ASN003 (0)
AUM302 (0)
BGT226 (0)
DS-7423 (0)
ETP-47187 (0)
GDC-0349 (0)
GSK1059615 (0)
HEC68498 (0)
IBL-202 (0)
IBL-301 (0)
MTX-211 (0)
PIK-75 (0)
SAR260301 (0)
SF1126 (0)
SF2523 (0)
SF2535 (0)
SL-901 (0)
SRX3177 (0)
TG 100-115 (0)
TOP216 (0)
VCD-597 (0)
VS-5584 (0)
WYE-125132 (0)
PQR309 (0)
NSC311152 (0)
inhibitors of the PI3K/AKT/mTOR pathway (0)
VT-11CR (0)
PX 866 (0)
SAR245409 (0)
RTB101 (43)
PF-05212384 (31)
RG7440 (27)
chidamide (23)
GDC-0941 (22)
AN2025 (20)
GSK2126458 (17)
CUDC-907 (8)
rigosertib (7)
LY294002 (7)
PF-04691502 (6)
RP6530 (6)
LY3023414 (5)
GDC-0980 (4)
A66 (3)
enzastaurin (3)
GDC-0084 (3)
PI-103 (2)
AEZS 136 (1)
AEZS-129 (1)
AZD8835 (1)
BAY 1082439 (1)
CB-006-3 (1)
DFN-529 (1)
KU-0060648 (1)
OP-11 (1)
SB02024 (1)
SRX3262 (1)
SAR245408 (1)
CBL0102 (1)
ASN003 (0)
AUM302 (0)
BGT226 (0)
DS-7423 (0)
ETP-47187 (0)
GDC-0349 (0)
GSK1059615 (0)
HEC68498 (0)
IBL-202 (0)
IBL-301 (0)
MTX-211 (0)
PIK-75 (0)
SAR260301 (0)
SF1126 (0)
SF2523 (0)
SF2535 (0)
SL-901 (0)
SRX3177 (0)
TG 100-115 (0)
TOP216 (0)
VCD-597 (0)
VS-5584 (0)
WYE-125132 (0)
PQR309 (0)
NSC311152 (0)
inhibitors of the PI3K/AKT/mTOR pathway (0)
VT-11CR (0)
PX 866 (0)
SAR245409 (0)
›
Associations
(16)
News
Trials
Search handles
@PTarantinoMD
Search handles
@PTarantinoMD
Filter by
Latest
over1year
In CALGB 40601 PIK3CA mutations were predictive and prognostic, driven by luminal subtype esp LumB - work by Paola Zagami. In same poster discussion, intriguing early data of adding PI3Ki MEN1611 to anti HER2 Rx by Martine Piccart. @UNCBreastSPORE #SABCS22 @ALLIANCE_org (@DrLisaCarey)
over 1 year ago
PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha)
|
PIK3CA mutation
|
MEN1611
almost4years
The wonders of #precisionmedicine Stunning response to alpelisib+trastuzumab in highly pretreated HER2+ MBC patient B-PRECISE01 trial of PI3K-inhibitor MEN1611 + trastuzumab (+- fulv) ongoing in @IEOufficiale, PI @curijoey @OncoAlert #bcsm (@PTarantinoMD)
almost 4 years ago
Clinical
|
HER-2 (Human epidermal growth factor receptor 2)
|
Herceptin (trastuzumab) • Piqray (alpelisib) • MEN1611
Share
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login